Stefan Zahler
chemistry
Institut Pasteur de Bangui
Germany
Biography
Adjunct Professor Group Leader Head of Imaging Facility,University of Munich Department of Pharmacy - Center for Drug Research Pharmaceutical Biology Butenandtstr. 5-13 81377 Munich,Angiogenesis, the formation of new blood vessels is important for physiological (e.g. wound healing) and pathological (e.g. tumor growth) processes. We are interested in inhibiting angiogenesis mainly in the tumor context as very promising therapeutic option. The molecular target structures we currently investigate are the kinase CDK5 and the cytoskeleton proteins tubulin and actin. By using and characterizing novel inhibitors of natural origin (e.g. isolated from myxobacteria) we gain insight into basic cell biological questions, and try to establish innovative classes of potential therapeutics. In a further approach, we try to understand basic concepts of angiogenesis by manipulating cellular behaviour via nanoagents. like, e.g. structured surfaces, hygrogels, nanoparticles or artificial membranes.
Research Interest
Imaging Facility
Publications
-
New natural products identified by combined genomics-metabolomics profiling of marine Streptomyces sp. MP131-18.
-
Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT.